Get the Stockscreener App
14.86
0.41%
0.06
After Hours:
14.82
-0.04
-0.27%
Immunic Inc stock is traded at $14.86, with a volume of 87,737.
It is up +0.41% in the last 24 hours and up +16.37% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$14.80
Open:
$14.78
24h Volume:
87,737
Relative Volume:
0.33
Market Cap:
$202.42M
Revenue:
-
Net Income/Loss:
$-104.29M
P/E Ratio:
-2.4632
EPS:
-6.0329
Net Cash Flow:
$-81.45M
1W Performance:
-3.57%
1M Performance:
+16.37%
6M Performance:
+138.33%
1Y Performance:
+104.35%
1-Day Range:
$14.69
$15.20
1-Week Range:
$14.50
$15.69
52-Week Range:
$5.062
$15.84
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
14.86 | 209.36M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Form 4 Immunic Inc For: 29 June By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton awarded 50,740 stock options at $10.90 - Stock Titan
Immunic (IMUX) director receives 25,370 fully vested options - Stock Titan
Immunic (IMUX) director receives grant of 25,370 fully vested options - Stock Titan
Immunic (NASDAQ: IMUX) director receives 25,370 stock options grant - Stock Titan
Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips receives 25,370 fully vested stock options - Stock Titan
IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant - Stock Titan
IMMUNIC (IMUX) CFO awarded stock options for 120,000 common shares - Stock Titan
IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price - Stock Titan
[Form 4] IMMUNIC, INC. Insider Trading Activity - Stock Titan
Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting - Stock Titan
Immunic, Inc.(NasdaqCM: IMUX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Price to earnings forward of Immunic, Inc. – BOATS:IMUX - TradingView
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling - biocentury.com
IMUX Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Immunic, Inc. – MUN:10V - TradingView
Price to book forward of Immunic, Inc. – MUN:10V - TradingView
Enterprise value to EBITDA forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Immunic (IMUX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to sales forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Enterprise value to EBIT forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Immunic Inc (FRA:10V) Stock Price & 30 Year Financial Data - GuruFocus
Eqs-News: Immunic to Present Additional Phase - Moomoo
Immunic consensus stays bullish, analysts back IMUX shares - AD HOC NEWS
Immunic Inc (IMUX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMUXImmunic Inc Stock Price and Quote - Finviz
Immunic Inc (IMUX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunic Inc (IMUX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunic Inc (IMUX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunic Inc (IMUX) Institutional Confidence - TradingKey
Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - mcduffieprogress.com
Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunic Inc (IMUX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunic Inc (IMUX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunic Inc Stock (US45256V1061): Biotech share in focus after recent volatility - AD HOC NEWS
Immunic to showcase IMU-856 research at June conferences - Proactive financial news
Immunic to Participate in Investor, Industry and Scientific Conferences in June - AD HOC NEWS
Biotech firm Immunic plans IMU-856 talk at Dublin symposium - Stock Titan
IMUX Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Pipeline ProgressEarnings Cycle Outlook - newsline.com
Immunic stock (US45256V1061): Pipeline updates keep investor focus on late-stage catalysts - AD HOC NEWS
Immunic Inc. (IMUX) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Sharp SelloffEarnings Sentiment Score - newsline.com
H.C. Wainwright Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Cost of goods sold of Immunic, Inc. – DUS:10V - TradingView
IMUX Q1 2026 Earnings: EPS Misses Estimates, Stock Dips 3.24%Final Results - newsline.com
IMMUNIC (IMUX) CEO Erik Lundgren files initial Form 3 insider report - Stock Titan
MS expert takes the helm - European Biotechnology Magazine
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):